Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedaxis, LLC

About this trial

Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound care practice in use of advanced wound care treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

At least 18 years old.

The index wound (i.e. current episode of the wound or ulceration) has been present for greater than 4 weeks prior to SV 1 and has had less than 1 year of documented medical treatment, as of the subject's consent for the study participation.

The index wound is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1.

Subject understands and is willing to participate in the clinical study and can comply with weekly visits.

Disqualifiers

The index ulcer will be the largest ulcer if two or more VLUs are present and will be the only one evaluated in the study. If other Ulcerations are present on the same leg, they must be more than 2cm distant from index ulcer.

Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool.

All wounds using the Sandy Grading System, except those in the exclusion criteria. (See Appendix A for definitions)

All wounds as per the CDC Surgical Wound Classification, with the exception of Class IV or dirty infected wounds, SSI - Deep incisional and organ space. (See Appendix A for definitions)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Study Device Debridement

    Device

    debritom+ water jet debridement

  • SOC Debridement

    Device

    Sharp Scalpel

Treatment groups

180 Participants
are divided into 2 treatment groups
Group A: debritom+Experimental treatment 1 intervention
Group B: Sharp ScalpelActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Wound Closure

Time to heal

Time frame
20 weeks

Secondary outcomes

1

Complications

Incidence of all index wound-related complications (eg. cellulitis or Infection), hospitalization, wound recurrence

Time frame
20 weeks
2

Advanced Wound Care Treatments

Number of successful advanced wound care treatments placed (eg. Negative Pressure Wound Therapy /grafts)

Time frame
20 weeks
3

Cost

Cost of Treatment (including Advance Wound Care) and including any index wound-related, event-driven complications using patient records or Medicare reimbursement method.

Time frame
20 weeks
4

Healed Proportion

Proportion of wounds completely healed

Time frame
20 weeks

Other outcomes

1

Unhealed Proportion

Proportion of wounds not completely healed

Time frame
20 weeks
2

PAR

Percent Area Reduction of Wound

Time frame
20 weeks
3

AWC Failure

Number of failures in regard to advanced wound care treatments

Time frame
20 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Medaxis, LLC

Lead sponsor

NAMSA

Collaborator